Cardiology expert Ethan Weiss describes the difference between ANGPTL4 and ANGPLT3, the rationale for lowering remnant cholesterol,...

CEO Lisa Deschamps describes this now clinical program for frontotemporal dementia, and Aviado's broader platform for using gene...

Rahul Dhanda describes the technology that Syntis uses to coat the upper region of the small intestine to modulate nutrient uptake, and...

After announcing a partnership expansion with Ipsen on Friday, Zhen Su describes how to succeed against cold tumors where T-cells are not...

Kevin Lind explains how patients randomized to therapy and placebo crossover patients are seeing comparable reductions in seizure levels....

Sushil Patel describes Replimune's ASCO and follow-on data from last week in the context of PD-1 response rates and competitor data from...

Paula Ragan describes the launch of this medicine that was approved at the end of April and previews an upcoming data announcement X4...

Joseph Payne describes data from the first four patients with CF to receive this inhaled mRNA at #ECFS2024. He also summarizes Arcturus'...

Daniel Oliver describes how Rejuvenate believes this program could have utility against arrhythmias and heart failure in both humans and...

Will Lewis describes last week's data and what means not just for bronchiectasis but also as a broader proof of concept for DPP1...

From the NYSE, Vlad Coric covers programs including protein degradation, ADCs, myostatin inhibition, the ion channel programs, and...

Akash Bakshi explains how YourChoice is leveraging learnings about how men who are vitamin A deficient are infertile or subfertile to...

At Moderna's analyst meeting at #ASCO24 in Chicago, Stéphane Bancel shows the Kaplan-Meier curve separation over time for the neoantigen...

Rachel Haurwitz elaborates on the data update for CB-010 that was presented at ASCO and describes why the company will push back the...

Tim Clackson explains how IDRX-42 has been designed to eliminate resistance mutations that the current standard of care cannot handle,...

John Oyler discusses the company's marketed BTK and PD-1 therapies, and highlights a handful of programs and targets in the pipeline like...

Aron Knickerbocker describes the benefits of focusing on the CD-25 binding portion of IL-2 and discusses some data presented at ASCO. He...

Terry Rosen describes data presented at ASCO for TIGIT in upper GI cancers, adenosine in late state colorectal cancer, and non-ASCO data...

Global Head of Oncology Ken Keller and Chief Operating Officer Hiroyuki Okuzawa describe the significance of today's data and also...

Dan Paterson gives background on the rolling submission the company started this week in a type of ovarian cancer, with his thoughts on...